Cancer

Patient sample and mouse studies suggest inhibiting glutamine uptake in cancer-associated prostate fibroblasts could help treat prostate cancers resistant to androgen receptor antagonists. In prostate cancer patients, high plasma levels of glutamine correlated with tumor insensitivity to Xtandi enzalutamide or other androgen receptor antagonists. In a castrated xenograft mouse model of prostate cancer, Xtandi plus a tool compound that inhibits glutamine uptake decreased tumor volume compared with Xtandi plus vehicle. Next steps include testing inhibitors of glutamine uptake and metabolism in patients with androgen receptor antagonist-resistant prostate cancer...